4 ms·
This is a bad business plan. Sure, they make a lot of money now, but they are curing all of their customers. Soon they won't have any left. Typical shortsighte
by jeffdavis 12y ago
This is a bad business plan. Sure, they make a lot of money now, but they are curing all of their customers. Soon they won't have any left.
Typical shortsighted focus on profits this quarter, without a sustainable business model.
- adventured 12y agoI assume this is a snark comment, but it is a fascinating discussion. Typically it's claimed big pharma & co. intentionally withhold, avoid creating, or would never pursue cures because it's not good for business. Then when they finally produce a cure, people get upset about the price. Short of being a non-profit or charity, they're damned if they do / don't. I think if Gilead can input $1 billion for development, and yield $100 billion on a cure (minus some comparatively modest marketing expenses), that's an excellent business model. ($80k * 1.x million hep c patients in the US that get their cure; assuming only a portion of the 3.x million in the US end up taking Gilead's drugs)